3,5-dimethyl-4-vinylisoxazole | 59402-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3,5-dimethyl-4-vinylisoxazole
• 英文别名: 3,5-Dimethyl-4-vinyl-isoxazol；4-Ethenyl-3,5-dimethyl-1,2-oxazole
• CAS: 59402-51-6
• 化学式: C₇H₉NO
• mdl: MFCD01082863
• 分子量: 123.155
• InChiKey: RYIHZFZTDJNDGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-dimethyl-4-vinylisoxazole 在 溴 作用下， 生成 4-(1,2-dibromo-ethyl)-3,5-dimethyl-isoxazole
  参考文献：
  名称：

  杂环系统的乙烯基衍生物及其聚合物：异恶唑衍生物

  摘要：

  3，5-二甲基-4-乙烯基异恶唑（3）是由戊烷-2，4-二酮通过1-（3，5-二甲基异恶唑-4-基）乙醇（2）通过两种不同的方法制备的，其中一种总收率超过75％。在自由基引发剂的存在下，化合物（3）被转化为具有异恶唑侧链的聚合物。

  DOI：

  10.1039/p19760000570
• 作为产物：
  描述：

  4-(2-氯乙基)-3,5-二甲基异噁唑 、 氢氧化钾 以70%的产率得到
  参考文献：
  名称：

  ISMAILOV, V. A.;BAJRAMOV, M. R.;SADYXOV, N. S.;GUSEJNOVA, R. A., AZERB. XIM. ZH.,(1988) N, S. 73-77

  摘要：

  DOI：

文献信息

• Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors
  作者：A. Keeley、P. Ábrányi-Balogh、G. M. Keserű

  DOI：10.1039/c8md00327k

  日期：——

  A fragment library of electrophilic small heterocycles was characterized through cysteine-reactivity and aqueous stability tests that suggested their potential as covalent warheads.

  通过半胱氨酸反应性和水稳定性测试，对亲电性小杂环片段库进行了表征，结果表明它们有潜力作为共价战斗头。
• [EN] 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION<br/>[FR] 4,6-DIARYLAMINOTHIAZINES À TITRE D'INHIBITEURS DE BACE1 ET LEUR UTILISATION POUR RÉDUIRE LA PRODUCTION DES BÊTA-AMYLOÏDES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014098831A1

  公开（公告）日：2014-06-26

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -S02C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z together can be absent.

  化合物的结构式（I），包括其药用盐，如下所示：（I），其中R1和R2分别是氢或-CH3；或者R1和R2可以通过添加-(CH2)4-在环中连接在一起；R3是氢或C1-C3烷基；Y和Z分别是C6-C10芳基或5-10成员杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C=OC1-4烷基、-S02C1-4烷基和C2-C4炔基的0-3取代基取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3取代基取代；L为-NHCO-，或者是单键；而L和Z可以缺失。
• 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150329506A1

  公开（公告）日：2015-11-19

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R 1 and R 2 are independently hydrogen, or —CH 3 ; or R 1 and R 2 can join together in a ring by adding —(CH 2 ) 4 —; R 3 is hydrogen or C 1 -C 3 alkyl; Y and Z are independently a C 6 -C 10 -aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, —C═OC 1-4 alkyl, —SO 2 C 1-4 alkyl, and C 2 -C 4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, hydroxyC 1-6 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, and C 2 -C 4 alkynyl; L is —NHCO—, or is a single bond; and L and Z together can be absent.

  本文列出了公式（I）的化合物，包括其中的药物可接受的盐：（I）其中R1和R2分别为氢或-CH3；或R1和R2可以通过添加-(CH2)4-形成环；R3为氢或C1-C3烷基；Y和Z分别为C6-C10芳基或5-10成员的杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C═OC1-4烷基、-SO2C1-4烷基和C2-C4炔基的0-3个取代基进行取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3个取代基进行取代；L为-NHCO-或单键；L和Z可以一起不存在。
• Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents
  作者：Yong-Jin Wu、Jason Guernon、Fukang Yang、Lawrence Snyder、Jianliang Shi、Andrea Mcclure、Ramkumar Rajamani、Hyunsoo Park、Alicia Ng、Hal Lewis、ChiehYing Chang、Dan Camac、Jeremy H. Toyn、Michael K. Ahlijanian、Charles F. Albright、John E. Macor、Lorin A. Thompson

  DOI：10.1021/acsmedchemlett.5b00432

  日期：2016.3.10

  By targeting the flap backbone of the BACE1 active site, we discovered 6-dimethylisoxazole-substituted biaryl aminothiazine 18 with 34-fold improved BACE1 inhibitory activity over the lead compound 1. The cocrystal structure of 18 bound to the active site indicated two hydrogen-bond interactions between the dimethylisoxazole and threonine 72 and glutamine 73 of the flap. Incorporation of the dimethylisoxazole substitution onto the related aminothiazine carboxamide series led to pyrazine-carboxamide 26 as a very potent BACE1 inhibitor (IC50 < 1 nM). This compound demonstrated robust brain A beta reduction in rat dose-response studies. Thus, compound 26 may be useful in testing the amyloid hypothesis of Alzheimer's disease.
• ISMAILOV, V. A.;BAJRAMOV, M. R.;SADYXOV, N. S.;GUSEJNOVA, R. A., AZERB. XIM. ZH.,(1988) N, S. 73-77
  作者：ISMAILOV, V. A.、BAJRAMOV, M. R.、SADYXOV, N. S.、GUSEJNOVA, R. A.

  DOI：——

  日期：——